Ultra-sensitive, tumor-informed ctDNA profiling in pembrolizumab-treated esophagogastric cancer patients predicts clinical responses.
Nixon AB, Navarro FCP, Zhou KI, Abbott C, McDaniel L, Howard L, Brady JC, Liu Y, Jia J, Niedzwiecki D, Strickler J, Boyle SM, Chen RO, Uronis H.
Nixon AB, et al. Among authors: zhou ki.
Res Sq [Preprint]. 2024 Dec 18:rs.3.rs-5349536. doi: 10.21203/rs.3.rs-5349536/v1.
Res Sq. 2024.
PMID: 39764133
Free PMC article.
Preprint.